Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients

Breast Cancer Research and Treatment

Volumn 115, Issue 2, 2009, Pages 359-363

  Byrski, T ^a   Huzarski, T ^a   Dent, R ^b   Gronwald, J ^a   Zuziak, D ^c   Cybulski, C ^a   Kladny, J ^a   Gorski, B ^a   Lubinski, J ^a   Narod, S A ^d  

^a POMERANIAN MEDICAL UNIVERSITY   (Poland)

^b DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

^c Oncological Hospital   (Poland)

^d WOMEN S COLLEGE HOSPITAL   (Canada)

Author keywords

BRCA1; Cisplatin

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ONDANSETRON; PLATINUM;

ADULT; ARTICLE; BREAST; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER PATIENT; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; LYMPH NODE; MASTECTOMY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; ONCOGENE; PRIORITY JOURNAL; TREATMENT RESPONSE;

ADULT; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CISPLATIN; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MASTECTOMY; MIDDLE AGED; MUTATION; NEOADJUVANT THERAPY; UBIQUITIN-PROTEIN LIGASES;

EID: 67349284098     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-008-0128-9     Document Type: Article

References (20)

1. JR Gralow HJ Burstein W Wood 2008 Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease J Clin Oncol 26 814 819 10.1200/JCO.2007.15.3510
2. C Liedtke C Mazouni KR Hess 2008 Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer J Clin Oncol 10 1275 1281 10.1200/JCO.2007.14.4147
3. SR Lakhani J Jacquemier JP Sloane 1998 Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations J Natl Cancer Inst 90 1138 1145 10.1093/jnci/90.15.1138
4. WD Foulkes K Metcalfe P Sun 2004 Estrogen receptor status in BRCA1- and BRCA2-related breast cancer: the influence of age, grade, and histological type Clin Cancer Res 10 2029 2034 10.1158/1078-0432.CCR-03-1061
5. MM Tilanus-Linthorst IM Obdeijn WC Hop 2007 BRCA1 mutation and young age predict fast breast cancer growth in the Dutch, United Kingdom, and Canadian magnetic resonance imaging screening trials Clin Cancer Res 13 7357 7362 10.1158/1078-0432.CCR-07-0689
6. ME Robson PO Chappuis J Satagopan 2004 A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment Breast Cancer Res 6 R8 R17 10.1186/bcr658
7. G Rennert S Bisland-Naggan O Barnett-Griness 2007 Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations N Engl J Med 357 115 123 10.1056/NEJMoa070608
8. RD Kennedy JE Quinn PB Mullan PG Johnston DP Harkin 2004 The role of BRCA1 in the cellular response to chemotherapy J Natl Cancer Inst 96 1659 1668
9. JE Quinn RD Kennedy PB Mullan 2003 BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis Cancer Res 6319 6221 6228
10. A Bhattacharyya US Ear BH Koller RR Weichselbaum DK Bishop 2000 The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin J Biol Chem 275 23899 23903 10.1074/jbc.C000276200
11. C Chabalier C Lamare C Racca M Privat A Valette F Larminat 2003 BRCA1 down-regulation leads to premature inactivation of spindle checkpoint and confers paclitaxel resistance Cell Cycle 5 1001 1007
12. C Zhou JL Smith J Liu 2003 Role of BRCA1 in cellular resistance to paclitaxel and ionizing radiation in an ovarian cancer cell line carrying a defective BRCA1 Oncogene 22 2396 2404 10.1038/sj.onc.1206319
13. N Shafee CR Smith S Wei 2008 Cancer stem cells contribute to cisplatin resistance in BRCA1-p53-mediated mouse tumours Cancer Res 68 3243 3250 10.1158/0008-5472.CAN-07-5480
14. MP Decatris S Sundar KJ O'Byrne 2004 Platinum-based chemotherapy in metastatic breast cancer: current status Cancer Treat Rev 4 53 81 10.1016/S0305-7372(03)00139-7
15. B Górski A Jakubowska T Huzarski 2004 A high proportion of founder BRCA1 mutations in Polish breast cancer families Int J Cancer 110 683 686 10.1002/ijc.20162
16. NCI National Cancer Institute (2003) Common terminology criteria for adverse events (CTCAE), version 3, June 10, 2004 update. National Cancer Institute, National Institutes of Health, Bethesda, MD
17. MA Richards IE Smith JM Dixon 1994 ABC of breast diseases Role Syst Treat Prim Operable Breast Cancer BMJ 309 1363 1366
18. AU Buzdar NK Ibrahim D Francis 2005 Significantly higher pathologic complete remission after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy. Results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer J Clin Oncol 23 3676 3685 10.1200/JCO.2005.07.032
19. I Cass RL Baldwin T Varkey R Moslehi SA Narod BY Karlan 2003 Improved survival in women with BRCA-associated ovarian carcinoma Cancer 97 2187 2195 10.1002/cncr.11310
20. N Turner A Tutt A Ashworth 2005 Targeting the DNA repair defect of BRCA tumours Curr Opin Pharmacol 5 388 393 10.1016/j.coph.2005.03.006